Media Image Professor Ros Eeles, Prostate Cancer Theme Lead Prostate cancer is the second most common cancer in men in the UK, with 130 cases diagnosed every day. This theme will improve treatment selection for patients and improve outcomes using advances in molecular diagnostics and treatment options for localised and metastatic disease. Theme aims To transform the clinical management of prostate cancer through minimising associated morbidity To reduce costs to the NHS through: Developing and evaluating targeted germline screening approaches to enrich detection of aggressive disease and reduce overdiagnosis Identifying genetic variants to further refine risk stratification for screening and translate into the clinic Discovering resistance mechanisms and developing treatments to overcome these Validating and qualifying molecular diagnostics for predictive, therapy response and surrogacy biomarkers Using novel imaging to improve surveillance, staging and treatment of localised and metastatic disease To develop more effective and safer radiation planning and delivery Theme lead Professor Ros Eeles (pictured above): expertise in identifying genetic variants that increase prostate cancer
Our impact: Prostate Cancer Our research has led to significant progress in uncovering of the genetic causes of prostate cancer and led to the development of new treatment options. Find out more
Targeted prostate cancer radiotherapy technique could cut treatment time from two months to two weeks
